共 50 条
- [1] Efficacy, Safety, and Patient-Reported Outcomes (PROs) of Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A Systematic Literature Review (SLR) [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S396 - S396
- [2] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) [J]. BLOOD, 2022, 140 : 7906 - 7907
- [7] Patient, Caregiver, and Physician Preferences for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S377
- [9] Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 474 - 482